Safimestomig

Cat. No.: S1434049

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

Safimestomig is an CD47/CD274 -targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control.

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Application Protocols

Only product-data-derived protocols may be listed here.

• Tested applications: Not specified for this item; refer to CoA/Spec Sheet.
• Recommended working concentrations/dilutions: Not specified for this item; refer to CoA/Spec Sheet.
• Positive controls/assay formats: Not specified for this item; refer to CoA/Spec Sheet.

Note: Please consult the lot-specific documentation or contact technical support for any available internal application notes.

Biological Roles

Item-specific biological function/mechanism: Not specified for this item; refer to CoA/Spec Sheet. No target, pathway, or MoA information is provided.

General considerations for research use of unknown small molecules:

• Treat as a non-characterized test article. Any observed biological activity should be corroborated with orthogonal assays and counterscreens to exclude artifacts (e.g., redox cycling, metal chelation, colloidal aggregation).
• Establish baseline ADME-relevant properties experimentally (permeability, plasma protein binding, metabolic stability) only if your study requires them; recognize that none are provided here.
• Record and report vehicle controls meticulously (DMSO concentration, pH, excipients) to maintain interpretability.

Compliance note: This product is supplied strictly for laboratory research use only. It is not a drug, diagnostic, or for human or veterinary use.

Buffer Applications

Item-specific buffer system guidance: Not specified for this item; refer to CoA/Spec Sheet.

General practice for dosing small molecules into aqueous buffers:

• Prepare concentrated stock in a miscible organic solvent (commonly DMSO), then dilute into buffer immediately before use to a final DMSO content typically ≤0.1–1% v/v.
• Choose buffer based on assay biology (e.g., PBS, HEPES, Tris). Absent pKa information, maintain pH 7.2–7.5 to minimize ionization extremes and precipitation risk.
• To mitigate precipitation or adsorption: add 0.01–0.05% non-ionic surfactant (e.g., Tween 80) if compatible with the assay.
• For light- or oxidation-sensitive compounds (unknown here), employ amberware and include antioxidants only if validated not to interfere in the assay.

Note: No specific buffer recipes or pH ranges are assigned to this item due to unavailable physicochemical data.

Green Alternatives

Given the absence of structural and solubility data, detailed substitution guidance is not item-specific. However, greener handling choices can be made when preparing stocks and assay solutions:

General greener considerations (literature/practice-based):

• Prefer lower-toxicity, biodegradable solvents when feasible for workup and cleaning: ethanol or isopropanol instead of dichloromethane for glassware rinses.
• For aqueous dosing, minimize DMSO to the lowest effective percentage (often ≤0.1–0.5% v/v) to reduce environmental impact and biological confounders.
• Explore co-solvent systems with improved safety profiles when compatible with the compound: ethanol/water mixes, citrate/phosphate buffers, or cyclodextrin inclusion to reduce organic solvent load.
• Use micro-scale formats and automated low-dead-volume dispensing to cut solvent consumption.

Trade-offs:

• Ethanol/water systems may not solubilize highly lipophilic entities as effectively as DMSO/DMF.
• Cyclodextrin complexation can alter apparent potency/availability; validate against control matrices.

Recommendation: Once the structure/solubility are known, consult solvent selection guides (e.g., CHEM21/ACS GCI) to map specific greener alternatives suitable for the compound’s polarity and functionality.

Pharmaceutical Uses

Item-specific pharmacopeial/excipient status: Not specified for this item; refer to CoA/Spec Sheet.

General context:

• This product is supplied for research use only and is not intended for formulation development intended for human or veterinary administration.
• If used as a research tool in pre-formulation studies, determine solubility, stability, and compatibility with typical excipients independently; none are provided here. Confirm no residual stabilizers or impurities (not specified for this item) that might confound studies.
• No compendial monographs (USP/EP/JP) or GMP manufacturing details are provided for this item.

Physical Properties

Item-specific properties (Product Data):

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• pKa/logP/logD: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility (water/organic): Not specified for this item; refer to CoA/Spec Sheet.

General characterization guidance (literature/practice-based):

• If solid, assess polymorphism and hygroscopicity by TGA/DSC and Karl Fischer. If liquid, record density and refractive index at 20–25 °C.
• Establish a solubility screen across DMSO, DMF, acetonitrile, methanol/ethanol, isopropanol, and aqueous buffers with 1–5% DMSO or surfactant (e.g., 0.01–0.1% Tween 80) as needed.
• Determine ionization by potentiometric or UV–pH titration to guide buffer selection and SPE method development.
• For analytical control, develop at least two orthogonal methods (e.g., RP-HPLC/UV and LC–MS). Record λmax if UV-active.

Note: Reported values in this section are not provided for this specific item; consult the CoA/Spec Sheet for authoritative item-specific data.

Quality and Grades

Item-specific quality (Product Data):

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Interpretation and expectations (general guidance):

• Compound-library items are commonly supplied at research grade, with purity often controlled by HPLC/UPLC and identity confirmed by LC–MS and/or NMR. For this specific item, exact specifications are not provided; consult the CoA for assay, identification methods, and acceptance criteria.
• If UV-Vis or MS data are included on the CoA, verify the observed mass/fragmentation and retention time match internal reference prior to screening.
• For quantitative biology or medicinal chemistry, consider additional in-house QC: qNMR for purity, chiral HPLC if stereochemistry is suspected, and water/volatile residue content by KF/GC if formulation is solvent-sensitive.
• Stabilizers/inhibitors: Not specified for this item; refer to CoA/Spec Sheet. If present in other products, inhibitors may affect bioassays and should be disclosed in protocols.

Documentation:

• Archive lot-specific CoAs and any in-house qualification results with method descriptions to ensure reproducibility across campaigns.

Reaction and Applications

Item-specific applications (Product Data): Not specified for this item; refer to CoA/Spec Sheet.

General use context for compound-library entries:

• Screening and hit identification: Employed as a test article in biochemical, biophysical, or cell-based assays to probe pathways or target classes. No target specificity is provided for this item.
• Reference control and method development: Can serve as a generic small-molecule control for validating assay window, LC–MS response, or sample processing workflows where a non-endogenous analyte is needed.
• Profiling: Evaluate intrinsic fluorescence/UV properties to assess interference in readouts (e.g., FRET, ALPHA, TR-FRET), and check redox activity or aggregation (e.g., detergent sensitivity) to flag assay artifacts.

Practical tips (general):

• Start with 10 mM stocks in dry DMSO; filter through 0.2 µm PTFE if particulate is observed. Confirm concentration by UV or quantitative NMR when possible.
• Assess chemical stability in assay-relevant buffers (pH 6–8) and under light/oxidative conditions. Use amberware if chromophores are suspected.
• Run counterscreens (e.g., detergent, redox, and PAINS substructure filters if/when structure becomes available) to reduce false positives.

Note: No reaction chemistry guidance is provided because the structure and functional groups are unknown for this item.

Reaction Conditions

No reaction conditions can be recommended for Safimestomig because the structure, functional groups, and reactivity class are not provided in the Product Data.

General guidance:

• If you intend to derivatize or conjugate this material, obtain full structural information and stability data first. Select solvents, temperatures, and catalysts based on the specific functional groups present. Until then, avoid speculative chemistry that could generate hazardous byproducts or destroy the material.

Safety and Handling

Item-specific hazard information (Product Data):

• Signal Word: Not specified for this item; refer to SDS.
• H-Statements: Not specified for this item; refer to SDS.
• GHS Classification: Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.

General laboratory safety (professional guidance):

• Use in a fume hood with standard PPE: lab coat, safety glasses, and appropriate chemically resistant gloves (typically nitrile). Avoid inhalation of dust/aerosols and repeated skin contact.
• Prevent cross-contamination of screening libraries by working with clean, dry tools; use single-use tips and pre-labeled aliquot vials.
• Unknown reactivity: keep away from strong oxidizers/reducers, strong acids/bases, and reactive metals until compatibility is known.
• First aid (overview; defer to SDS): on skin/eye contact, rinse with water for ≥15 minutes; if inhaled, move to fresh air; if ingested, rinse mouth. Seek medical attention if symptoms occur.
• Waste disposal: collect in halogenated or non-halogenated organic waste depending on solvent matrix. Follow institutional and local regulations.

Special risks (unknowns):

• Sensitization, genotoxicity, or environmental hazard profiles are not provided. Handle as potentially hazardous until specific SDS data are available.
• Avoid aerosolization and minimize DMSO-mediated dermal exposure for any bioactive screening compound.

Solvent Selection

Item-specific solubility/solvent guidance: Not specified for this item; refer to CoA/Spec Sheet.

General strategy for small-molecule library compounds (practice-based):

• Primary stock solvent: DMSO is typically first choice due to broad solvency and assay compatibility (≤0.1–1% v/v in final wells). Verify stability in DMSO at storage temperature.
• Secondary options: DMF, acetonitrile, methanol/ethanol, or mixtures thereof. For basic compounds, add a small amount of acid (e.g., 0.1% TFA or HCl in MeOH); for acidic compounds, add base (e.g., 0.1% NH4OH) to enhance solubility. Implement only after compatibility checks.
• Aqueous dosing: Prepare intermediate dilutions in buffer immediately prior to use, limiting DMSO carryover. Consider surfactants (0.01–0.05% Tween 80 or Pluronic F-68) for hydrophobic entities.

Comparison (general):

• DMSO: highest solvency; may extract plastics; manage hygroscopic water uptake.
• ACN: volatile, LC–MS friendly; lower solvency for highly lipophilic compounds.
• MeOH/EtOH: protic, good for many mid-polar scaffolds; may affect some enzyme assays.
• PEG-400/co-solvent systems: useful for very lipophilic compounds; higher viscosity may complicate pipetting.

Recommendation: Run a 6–8 point solubility screen before committing to large-batch aliquoting.

Storage and Reconstitution

Item-specific (Product Data):

• Storage Conditions: Store at −20 °C.
• Shipped In: Ice chest + ice pads.

General guidance (for small-molecule library compounds):

• Primary containers: Store in tightly sealed, chemically compatible vials (preferably amber) under dry conditions. Add desiccant to secondary containment if feasible.
• Freeze–thaw: Minimize cycles by preparing single-use aliquots (e.g., 10–50 µL) of concentrated DMSO stocks. Record lot, concentration, and date on each aliquot.
• Reconstitution (if supplied as a dry solid; not specified for this item): Dissolve in anhydrous DMSO to prepare a typical 10 mM stock, then dilute as needed into assay media immediately before use. If solubility is poor, gently warm (≤40 °C) and vortex/sonicate briefly.
• Stability checks: Periodically inspect for precipitation, discoloration, or LC–MS degradation products. Discard if changes are observed.
• Light/air sensitivity: Unknown for this item; protect from light and air as a precaution until stability is confirmed.

Always defer to the lot-specific CoA/Spec Sheet and SDS for definitive handling and storage instructions beyond the general practices above.

Structure and Identity

Overview

• Item name: Safimestomig (SKU: S1434049)
• Category: Small molecules and compound library (小分子和化合物库)

Item-specific identifiers (Product Data):

• CAS: Not specified for this item; refer to CoA/Spec Sheet.
• CID: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general note):

• No structural information is provided in the Product Data. Without a molecular structure, functional groups, ring systems, or stereochemical elements cannot be described. Please consult the product’s CoA/Spec Sheet for definitive identity data prior to method development, quantitation, or regulatory documentation.

2D structure description (general guidance):

• In the absence of a structure, treat Safimestomig as an unnamed screening entity. If structure becomes available, document: core scaffold, heteroatoms (N/O/S/halogens), ionizable centers, and any stereocenters or atropisomerism. These elements strongly influence solubility profiles, storage stability, and analytical method selection.

Synthetic Utility

Item-specific synthetic roles and transformations cannot be described because no structural or functional group information is provided for Safimestomig.

General note:

• If the compound were to be used as a synthetic intermediate or reference standard, consult the structure (when available) to evaluate reactive handles (e.g., aryl halides for cross-coupling, acids/amines for amide formation, alcohols for esterification). Without such information, no credible synthetic planning guidance can be offered for this item.

Target Specificity

Only product-data-derived details may be listed here.

• Target/antigen: Not specified for this item; refer to CoA/Spec Sheet.
• Species selectivity: Not specified for this item; refer to CoA/Spec Sheet.
• Mechanism/class: Not specified for this item; refer to CoA/Spec Sheet.

Note: No target-binding or selectivity information is provided for Safimestomig in the Product Data.